Skip to content

US · BHST · AGRICULTURAL INPUTS

BioHarvest Sciences Inc. Common Stock (BHST) intrinsic value and stock valuation

$1.30as of 2026-11-21 · Mkt cap 39.16M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioHarvest Sciences Inc. Common Stock DCF and intrinsic value

InvestorsCraft values BHST with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BHST’s statements →

BioHarvest Sciences Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Basic Materials · Agricultural Inputs Vancouver, BC V6C 2T6 bioharvest.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$34.5M+143.9% 5y CAGRd
20142025
Net income
-$-11.13M
20142025
Free cash flow
-$-9.58M
20142025
Total equity
$25.5M
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$34.5M$25.2M$12.7M$5.5M$2.1M
Operating income-$-5.58M-$-6.99M-$-9.97M-$-10.61M-$-8.49M
Net income-$-11.13M-$-12.91M-$-12.56M-$-11.24M-$-9.83M
EPSd-$-604.56K-$-797.41K-$-928.31K-$-861.3K-$-789.56K
Operating cash flow-$-7.23M-$-6.68M-$-8.52M-$-9.24M-$-6.79M
Capital expenditure-$-2.35M-$-2.83M-$-1.47M-$-1.26M-$-1.64M
Free cash flow-$-9.58M-$-9.52M-$-10M-$-10.5M-$-8.43M
Total assets$47.7M$25M$15M$9.39M$10.2M
Total debt$14.1M$13.8M$22.3M$10.6M$2.66M
Net debt-$-8.92M$11.4M$17M$8.82M-$-1.46M
Total equity$25.5M$1.33M-$-14.85M-$-5.93M$2.85M
Cash and short-term investments$23M$2.39M$5.36M$1.74M$4.12M
Income statement
20252024202320222021
Revenue$34.5M$25.2M$12.7M$5.5M$2.1M
Cost of revenue$14M$11.3M$7.04M$4.28M$1.43M
Gross profit$20.5M$13.9M$5.63M$1.22M$670K
Research and development expenses$5.31M$4.8M$3.37M$2.31M$4.13M
Selling, general and administrative expenses$19.1M$14.7M$12.1M$9.35M$4.76M
Other expenses$1.6M$1.47M$150K$170K$270K
Operating expenses$26.1M$20.9M$15.6M$11.8M$9.16M
Cost and expenses$40.1M$32.2M$22.6M$16.1M$10.6M
Interest income$50K$0.00$0.00$0.00$0.00
Interest expense$2.72M$1.93M$1.96M$1.4M$810K
Depreciation and amortization$1.62M$1.25M$840K$710K$390K
Ebitda-$-6.71M-$-9.72M-$-9.76M-$-9.12M-$-8.64M
Operating income-$-5.58M-$-6.99M-$-9.97M-$-10.61M-$-8.49M
Total other income/expenses, net-$-5.48M-$-5.92M-$-2.6M-$-620K-$-1.34M
Income before tax-$-11.06M-$-12.9M-$-12.56M-$-11.24M-$-9.83M
Income tax expense$80K$10K$0.00$0.00$0.00
Net income-$-11.13M-$-12.91M-$-12.56M-$-11.24M-$-9.83M
Weighted average shares outstanding$18.4M$16.2M$13.5M$13.1M$12.5M
Weighted average diluted shares outstanding$18.4M$16.2M$13.5M$13.1M$12.5M
Balance sheet
20252024202320222021
Cash and short-term investments$23M$2.39M$5.36M$1.74M$4.12M
Net receivables$2.24M$1.34M$970K$720K$620K
Inventory$4.56M$3.65M$2.47M$1.38M$930K
Total current assets$30.5M$7.86M$9.05M$4.32M$5.67M
Property, plant and equipment, net$16.7M$16.8M$5.77M$4.91M$4.36M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$17.2M$17.1M$5.95M$5.07M$4.54M
Total assets$47.7M$25M$15M$9.39M$10.2M
Accounts payable$2.63M$3.52M$1.78M$1.07M$880K
Short-term debt$1.55M$4.68M$20.9M$8.89M$390K
Deferred revenue$490K$1.3M$840K$390K$0.00
Total current liabilities$7.68M$14.3M$26.5M$11.5M$2.92M
Long-term debt$12.6M$9.14M$1.43M$1.67M$2.27M
Deferred revenue, non-current$0.00$0.00$0.00$2.01M$1.82M
Total non-current liabilities$14.5M$9.41M$3.39M$3.8M$4.43M
Capital lease obligations$11.5M$9.91M$1.81M$2.01M$2.66M
Total liabilities$22.2M$23.7M$29.9M$15.3M$7.35M
Common stock$133M$97.8M$68.7M$65M$62.6M
Retained earnings-$-107.55M-$-96.42M-$-83.5M-$-70.94M-$-59.7M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$25.5M$1.33M-$-14.85M-$-5.93M$2.85M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$14.1M$13.8M$22.3M$10.6M$2.66M
Net debt-$-8.92M$11.4M$17M$8.82M-$-1.46M
Cash flow statement
20252024202320222021
Net income-$-11.13M-$-12.91M-$-12.56M-$-11.24M-$-9.83M
Depreciation and amortization$1.62M$1.25M$840K$710K$390K
Stock-based compensation$600K$600K$560K$1.35M$3.37M
Change in working capital-$-1.94M-$-560K$760K-$-310K-$-100K
Accounts receivable-$-1.1M-$-590K-$-20K-$-590K-$-270K
Inventory-$-900K-$-1.19M-$-1.09M-$-450K-$-830K
Accounts payable$0.00$1.04M$0.00$730K$0.00
Net cash provided by operating activities-$-7.23M-$-6.68M-$-8.52M-$-9.24M-$-6.79M
Investments in property, plant and equipment-$-2.35M-$-2.83M-$-1.47M-$-1.26M-$-1.64M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-2.37M-$-3.03M-$-1.47M-$-1.26M-$-1.64M
Common stock issued$25.1M$4.33M$530K$880K$7.47M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$30.2M$6.78M$13.6M$8.14M$10.8M
Net change in cash$20.6M-$-2.96M$3.62M-$-2.38M$2.33M
Cash at end of period$23M$2.39M$5.36M$1.74M$4.12M
Operating cash flow-$-7.23M-$-6.68M-$-8.52M-$-9.24M-$-6.79M
Capital expenditure-$-2.35M-$-2.83M-$-1.47M-$-1.26M-$-1.64M
Free cash flow-$-9.58M-$-9.52M-$-10M-$-10.5M-$-8.43M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioHarvest Sciences Inc. Common Stock

        BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.

        CEO
        Zaki Rakib
        Employees
        89
        Beta
        1.39

        Explore

        Frequently asked questions

        What is the intrinsic value of BioHarvest Sciences Inc. Common Stock (BHST)?

        BioHarvest Sciences Inc. Common Stock (BHST) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BHST undervalued?

        BHST trades at a price of $1.30 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.